Keyword: Regulus Therapeutics
The goal is to use Dicerna’s GalXC technology to silence previously inaccessible drug targets, thereby restoring liver function.
Biogen lost CFO Paul Clancy to Alexion but poached Jean-Paul Kress from Sanofi Genzyme, and VC Flagship brought on J.P. Morgan vet Berenson.
Probably hoping to help turn things around after clinical setbacks, microRNA biotech Regulus tapped the help of CRO Aptuit.
Under-pressure microRNA biotech Regulus has promoted Mark Deeg into a new role as CMO.
Embattled Regulus Therapeutics suffered another blow today after revealing AstraZeneca handed back rights to a clinical-stage NASH drug.
Scott Gottlieb was confirmed to lead FDA, neuroscientist Thomas Insel left Verily, Immunomedics' CEO and CSO stepped down.
Regulus Therapeutics has axed 30% of its workforce to conserve cash for its stuttering pipeline.
Regulus has bulked up its pipeline with two new drug candidates due to start trials next year, as it tries to get lead hep C candidate back on track.
Regulus Therapeutics saw its shares nosedive last month when the FDA put a clinical trial hold on its leading hep C candidate RG-101--but the company said this morning it hopes to get all of its ducks in a row for the FDA to lift the hold by the start of Q4.
Small cap Regulus Therapeutics has nabbed a $30 million credit facility from Oxford Finance that it said is sufficient to get it into 2018. Most of the money is already earmarked to back its Phase II clinical program for lead candidate RG-101.
